CALL/VERTEX PHARMACEUTICALS/700/0.1/20.06.25 | Market Closed - BOERSE MUENCHEN 11:57:06 17/05/2024 pm IST | ||
| 0.415 EUR | +9.21% |
|
| Current month | +67.34% | ||
| 1 month | -16.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.415 | +9.21% |
| 16/24/16 | 0.38 | -11.63% |
| 15/24/15 | 0.43 | +21.47% |
| 14/24/14 | 0.354 | -4.32% |
| 13/24/13 | 0.37 | +2.78% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 11:57 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG2SF4 |
| ISIN | DE000GG2SF42 |
| Date issued | 18/01/2024 |
| Strike | 700 $ |
| Maturity | 20/06/2025 (399 Days) |
| Parity | 10 : 1 |
| Emission price | 0.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.04 € |
|---|---|
| Lowest since issue | 0.244 € |
| Spread | 0.3 € |
| Spread % | 38.46% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Warrants
- Warrant
